ReviewViruses2021
Understanding Antibody Responses in Early Life: Baby Steps towards Developing an Effective Influenza Vaccine.
Review in Viruses, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 12 citations in OpenAlex.
- Total Immunoglobulin G Variation Through the Phenological Cycle of Migrant and Resident Lesser Long-Nosed Bats (Leptonycteris yerbabuenae) in the Drylands of Mexico and Its Relationship With Bacterial Killing-Ability of Plasma.Journal of experimental zoology. Part A, Ecological and integrative physiology · 2026Article
- Vaccine Responses in Early Age.Vaccines · 2026Review
- Article
- H1N1 challenge results in rapid recall of stem-specific immunity in HA stem nanoparticle-vaccinated newborn monkeys.JCI insight · 2025Article
- Young children have limited mucosal immunity when stimulated with an influenza vaccine in tonsil organoids.Research square · 2025Article
- Human airway epithelial B-cell activating factor is reduced in early life but is virally induced via JAK/STAT.The Journal of allergy and clinical immunology · 2025Article
- Antibody function predicts viral control in newborn monkeys immunised with an influenza virus HA stem nanoparticle.Nature communications · 2025Article
- State of pneumococcal vaccine immunity.Human vaccines & immunotherapeutics · 2024Article
- Juruaça virus taxonomy, tolerance and resistance to infection, and inflammatory response modulation in murine model.Npj viruses · 2024Article
- Article
- Biomarkers detected in cord blood predict vaccine responses in young infants.Frontiers in immunology · 2023Article
- Study Protocol for Preventing Early-Onset Pneumonia in Young Children Through Maternal Immunisation: A Multi-Centre Randomised Controlled Trial (PneuMatters).Frontiers in pediatrics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The immune system of young infants is both quantitatively and qualitatively distinct from that of adults, with diminished responsiveness leaving these individuals vulnerable to infection. Because of this, young infants suffer increased morbidity and mortality from respiratory pathogens such as influenza viruses. The impaired generation of robust and persistent antibody responses in these individuals makes overcoming this increased vulnerability through vaccination challenging. Because of this, an effective vaccine against influenza viruses in infants under 6 months is not available. Furthermore, vaccination against influenza viruses is challenging even in adults due to the high antigenic variability across viral strains, allowing immune evasion even after induction of robust immune responses. This has led to substantial interest in understanding how specific antibody responses are formed to variable and conserved components of influenza viruses, as immune responses tend to strongly favor recognition of variable epitopes. Elicitation of broadly protective antibody in young infants, therefore, requires that both the unique characteristics of young infant immunity as well as the antibody immunodominance present among epitopes be effectively addressed. Here, we review our current understanding of the antibody response in newborns and young infants and discuss recent developments in vaccination strategies that can modulate both magnitude and epitope specificity of IAV-specific antibody.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.